Following an abbreviated submission:
faricimab (Vabysmo®) is accepted for use within NHSScotland.
Indication under review: treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
Faricimab offers an additional treatment choice in the therapeutic class of antineovascularisation agents.
In two phase III studies faricimab was non-inferior to an anti-vascular endothelial growth factor treatment at week 24 for mean change from baseline in best-corrected visual acuity (BCVA) .
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice289KB (PDF)
Medicine details
- Medicine name:
- faricimab (Vabysmo)
- SMC ID:
- SMC2685
- Indication:
For the treatment of adult patients with visual impairment due to macular oedema secondary to branched and central retinal vein occlusion (BRVO and CRVO).
- Pharmaceutical company
- Roche
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 October 2024